Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Small interfering RNAs based on huntingtin trinucleotide repeats are highly toxic to cancer cells.

Murmann AE, Gao QQ, Putzbach WE, Patel M, Bartom ET, Law CY, Bridgeman B, Chen S, McMahon KM, Thaxton CS, Peter ME.

EMBO Rep. 2018 Feb 12. pii: e45336. doi: 10.15252/embr.201745336. [Epub ahead of print]

PMID:
29440125
2.

DISE: A Seed-Dependent RNAi Off-Target Effect That Kills Cancer Cells.

Putzbach W, Gao QQ, Patel M, Haluck-Kangas A, Murmann AE, Peter ME.

Trends Cancer. 2018 Jan;4(1):10-19. doi: 10.1016/j.trecan.2017.11.007. Epub 2018 Jan 8. Review.

PMID:
29413418
3.

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.

Cell Death Differ. 2018 Jan 23. doi: 10.1038/s41418-017-0012-4. [Epub ahead of print] Review.

PMID:
29362479
4.

Induction of DISE in ovarian cancer cells in vivo.

Murmann AE, McMahon KM, Haluck-Kangas A, Ravindran N, Patel M, Law CY, Brockway S, Wei JJ, Thaxton CS, Peter ME.

Oncotarget. 2017 Oct 4;8(49):84643-84658. doi: 10.18632/oncotarget.21471. eCollection 2017 Oct 17.

5.

Identification of DISE-inducing shRNAs by monitoring cellular responses.

Patel M, Peter ME.

Cell Cycle. 2017 Nov 1:0. doi: 10.1080/15384101.2017.1383576. [Epub ahead of print]

PMID:
29092660
6.

Many si/shRNAs can kill cancer cells by targeting multiple survival genes through an off-target mechanism.

Putzbach W, Gao QQ, Patel M, van Dongen S, Haluck-Kangas A, Sarshad AA, Bartom ET, Kim KA, Scholtens DM, Hafner M, Zhao JC, Murmann AE, Peter ME.

Elife. 2017 Oct 24;6. pii: e29702. doi: 10.7554/eLife.29702.

7.

Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.

Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, Mishra RK, Schiltz GE, Dubrovskyi O, Mazar AP, Peter ME, Zheng H, James CD, Burant CF, Chandel NS, Davuluri RV, Horbinski C, Stegh AH.

Cell Rep. 2017 May 30;19(9):1858-1873. doi: 10.1016/j.celrep.2017.05.014.

8.

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

Qadir AS, Ceppi P, Brockway S, Law C, Mu L, Khodarev NN, Kim J, Zhao JC, Putzbach W, Murmann AE, Chen Z, Chen W, Liu X, Salomon AR, Liu H, Weichselbaum RR, Yu J, Peter ME.

Cell Rep. 2017 Mar 7;18(10):2373-2386. doi: 10.1016/j.celrep.2017.02.037.

9.

"You Need to Be a Good Listener": Recruiters' Use of Relational Communication Behaviors to Enhance Clinical Trial and Research Study Accrual.

Morgan SE, Occa A, Potter J, Mouton A, Peter ME.

J Health Commun. 2017 Feb;22(2):95-101. doi: 10.1080/10810730.2016.1256356. Epub 2017 Jan 13.

PMID:
28085636
10.
11.

Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube.

Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E.

Cancer Discov. 2016 Dec;6(12):1342-1351. Epub 2016 Oct 7.

12.

MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment.

Kohlhapp FJ, Mitra AK, Lengyel E, Peter ME.

Oncogene. 2015 Nov 26;34(48):5857-68. doi: 10.1038/onc.2015.89. Epub 2015 Apr 13. Review.

13.

The role of CD95 and CD95 ligand in cancer.

Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P.

Cell Death Differ. 2015 May;22(5):885-6. doi: 10.1038/cdd.2015.25. No abstract available.

14.

miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma.

Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, Peng CY, Merkel TJ, Queisser MA, Ritner C, Zhang H, James CD, Sznajder JI, Chin L, Giljohann DA, Kessler JA, Peter ME, Mirkin CA, Stegh AH.

Genes Dev. 2015 Apr 1;29(7):732-45. doi: 10.1101/gad.257394.114.

15.

Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis.

Mitra AK, Chiang CY, Tiwari P, Tomar S, Watters KM, Peter ME, Lengyel E.

Oncogene. 2015 Nov 26;34(48):5923-32. doi: 10.1038/onc.2015.43. Epub 2015 Mar 23.

16.

The role of CD95 and CD95 ligand in cancer.

Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P.

Cell Death Differ. 2015 Apr;22(4):549-59. doi: 10.1038/cdd.2015.3. Epub 2015 Feb 6. Review. Erratum in: Cell Death Differ. 2015 May;22(5):885-6.

17.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

18.

CD95 and CD95L promote and protect cancer stem cells.

Ceppi P, Hadji A, Kohlhapp FJ, Pattanayak A, Hau A, Liu X, Liu H, Murmann AE, Peter ME.

Nat Commun. 2014 Nov 4;5:5238. doi: 10.1038/ncomms6238.

19.

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137. Epub 2014 Sep 19. Review.

20.

Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing.

Xu Y, Gao XD, Lee JH, Huang H, Tan H, Ahn J, Reinke LM, Peter ME, Feng Y, Gius D, Siziopikou KP, Peng J, Xiao X, Cheng C.

Genes Dev. 2014 Jun 1;28(11):1191-203. doi: 10.1101/gad.241968.114. Epub 2014 May 19.

21.

DICE: A novel tumor surveillance mechanism-a new therapy for cancer?

Peter ME.

Cell Cycle. 2014;13(9):1373-8. doi: 10.4161/cc.28673. Epub 2014 Apr 1.

22.

Death induced by CD95 or CD95 ligand elimination.

Hadji A, Ceppi P, Murmann AE, Brockway S, Pattanayak A, Bhinder B, Hau A, De Chant S, Parimi V, Kolesza P, Richards J, Chandel N, Djaballah H, Peter ME.

Cell Rep. 2014 Apr 10;7(1):208-22. doi: 10.1016/j.celrep.2014.02.035. Epub 2014 Mar 20.

23.

Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells.

Montes de Oca A, Guerrero F, Martinez-Moreno JM, Madueño JA, Herencia C, Peralta A, Almaden Y, Lopez I, Aguilera-Tejero E, Gundlach K, Büchel J, Peter ME, Passlick-Deetjen J, Rodriguez M, Muñoz-Castañeda JR.

PLoS One. 2014 Feb 25;9(2):e89525. doi: 10.1371/journal.pone.0089525. eCollection 2014.

24.

miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers.

Hua Y, Larsen N, Kalyana-Sundaram S, Kjems J, Chinnaiyan AM, Peter ME.

BMC Genomics. 2013 Mar 15;14:179. doi: 10.1186/1471-2164-14-179.

25.

Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.

De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D'Haese PC, Neven E.

Kidney Int. 2013 Jun;83(6):1109-17. doi: 10.1038/ki.2013.34. Epub 2013 Mar 13.

26.

MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells.

Ceppi P, Peter ME.

Oncogene. 2014 Jan 16;33(3):269-78. doi: 10.1038/onc.2013.55. Epub 2013 Mar 4. Review.

PMID:
23455327
27.

MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer.

Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E.

Cancer Discov. 2012 Dec;2(12):1100-8. doi: 10.1158/2159-8290.CD-12-0206. Epub 2012 Nov 21.

28.

CD95 is part of a let-7/p53/miR-34 regulatory network.

Hau A, Ceppi P, Peter ME.

PLoS One. 2012;7(11):e49636. doi: 10.1371/journal.pone.0049636. Epub 2012 Nov 14.

29.

Fas ligand-Fas signaling participates in light-induced apoptotic death in photoreceptor cells.

Chang Q, Peter ME, Grassi MA.

Invest Ophthalmol Vis Sci. 2012 Jun 20;53(7):3703-16. doi: 10.1167/iovs.11-8928.

30.

Influence of bicarbonate/low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells.

Fernández-Perpén A, Pérez-Lozano ML, Bajo MA, Albar-Vizcaino P, Sandoval Correa P, del Peso G, Castro MJ, Aguilera A, Ossorio M, Peter ME, Passlick-Deetjen J, Aroeira LS, Selgas R, López-Cabrera M, Sánchez-Tomero JA.

Perit Dial Int. 2012 May-Jun;32(3):292-304. doi: 10.3747/pdi.2010.00315. Epub 2012 Jan 3.

31.

miRConnect: identifying effector genes of miRNAs and miRNA families in cancer cells.

Hua Y, Duan S, Murmann AE, Larsen N, Kjems J, Lund AH, Peter ME.

PLoS One. 2011;6(10):e26521. doi: 10.1371/journal.pone.0026521. Epub 2011 Oct 26.

32.

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.

Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E.

Nat Med. 2011 Oct 30;17(11):1498-503. doi: 10.1038/nm.2492.

33.

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012.

Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry WS, Fulda S, Gottlieb E, Green DR, Hengartner MO, Kepp O, Knight RA, Kumar S, Lipton SA, Lu X, Madeo F, Malorni W, Mehlen P, Nuñez G, Peter ME, Piacentini M, Rubinsztein DC, Shi Y, Simon HU, Vandenabeele P, White E, Yuan J, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2012 Jan;19(1):107-20. doi: 10.1038/cdd.2011.96. Epub 2011 Jul 15. Review.

34.

Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner.

Kircelli F, Peter ME, Sevinc Ok E, Celenk FG, Yilmaz M, Steppan S, Asci G, Ok E, Passlick-Deetjen J.

Nephrol Dial Transplant. 2012 Feb;27(2):514-21. doi: 10.1093/ndt/gfr321. Epub 2011 Jul 12.

35.

Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.

Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, Hua YJ, Lengyel E, Peter ME.

Int J Cancer. 2012 Apr 15;130(8):1787-97. doi: 10.1002/ijc.26190. Epub 2011 Aug 16.

36.

Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E.

Clin Cancer Res. 2011 Jun 15;17(12):4042-51. doi: 10.1158/1078-0432.CCR-10-3387. Epub 2011 May 6.

37.

Programmed cell death: Apoptosis meets necrosis.

Peter ME.

Nature. 2011 Mar 17;471(7338):310-2. doi: 10.1038/471310a. No abstract available.

PMID:
21412328
38.

miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1.

Schickel R, Park SM, Murmann AE, Peter ME.

Mol Cell. 2010 Jun 25;38(6):908-15. doi: 10.1016/j.molcel.2010.05.018.

39.

Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid.

Bajo MA, Pérez-Lozano ML, Albar-Vizcaino P, del Peso G, Castro MJ, Gonzalez-Mateo G, Fernández-Perpén A, Aguilera A, Sánchez-Villanueva R, Sánchez-Tomero JA, López-Cabrera M, Peter ME, Passlick-Deetjen J, Selgas R.

Nephrol Dial Transplant. 2011 Jan;26(1):282-91. doi: 10.1093/ndt/gfq357. Epub 2010 Jun 22.

PMID:
20571097
40.

CD95 promotes tumour growth.

Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME.

Nature. 2010 May 27;465(7297):492-6. doi: 10.1038/nature09075. Erratum in: Nature. 2011 Jul 14;475(7355):254. Nature. 2011 Mar 10;471(7337):254. Nature. 2012 Nov 29;491(7426):784.

41.

Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer.

Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, Villadsen SB, Gao S, Ostenfeld MS, Borre M, Peter ME, Ørntoft TF, Kjems J, Clark SJ.

Int J Cancer. 2011 Mar 15;128(6):1327-34. doi: 10.1002/ijc.25461.

42.

Synthesis of a high-purity chemical library reveals a potent inducer of oxidative stress.

Cui J, Matsumoto K, Wang CY, Peter ME, Kozmin SA.

Chembiochem. 2010 Jun 14;11(9):1224-7. doi: 10.1002/cbic.201000193. No abstract available.

43.

Growth of gamma glycine crystal and its characterisation.

Peter ME, Ramasamy P.

Spectrochim Acta A Mol Biomol Spectrosc. 2010 May;75(5):1417-21. doi: 10.1016/j.saa.2010.01.011. Epub 2010 Feb 6.

PMID:
20299279
44.

Targeting of mRNAs by multiple miRNAs: the next step.

Peter ME.

Oncogene. 2010 Apr 15;29(15):2161-4. doi: 10.1038/onc.2010.59. Epub 2010 Mar 1. Review.

PMID:
20190803
45.

Regulating cancer stem cells the miR way.

Peter ME.

Cell Stem Cell. 2010 Jan 8;6(1):4-6. doi: 10.1016/j.stem.2009.12.006.

46.

Cell death in the colonic epithelium during inflammatory bowel diseases: CD95/Fas and beyond.

Chen L, Park SM, Turner JR, Peter ME.

Inflamm Bowel Dis. 2010 Jun;16(6):1071-6. doi: 10.1002/ibd.21191. Review.

PMID:
20049945
47.

CD95 is cytoprotective for intestinal epithelial cells in colitis.

Park SM, Chen L, Zhang M, Ashton-Rickardt P, Turner JR, Peter ME.

Inflamm Bowel Dis. 2010 Jun;16(6):1063-70. doi: 10.1002/ibd.21195.

PMID:
20049944
48.

The role of let-7 in cell differentiation and cancer.

Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME.

Endocr Relat Cancer. 2010 Jan 29;17(1):F19-36. doi: 10.1677/ERC-09-0184. Print 2010 Mar. Review.

49.

An interview with Dr. Marcus E. Peter on his highly cited paper published in Cell Cycle.

Peter ME.

Cell Cycle. 2009 Aug;8(15):2325. Epub 2009 Aug 1. No abstract available.

PMID:
19571670
50.

Identification of an N-terminal recognition site in TLR9 that contributes to CpG-DNA-mediated receptor activation.

Peter ME, Kubarenko AV, Weber AN, Dalpke AH.

J Immunol. 2009 Jun 15;182(12):7690-7. doi: 10.4049/jimmunol.0900819.

Supplemental Content

Loading ...
Support Center